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What is Already Known about this Subject {#bcp13745-sec-0005}
========================================

There are currently no pharmacological treatments that have been approved for the treatment of impaired speech or swallowing in patients with amyotrophic lateral sclerosis (ALS); however, dextromethorphan/quinidine, a drug approved for the treatment of emotional lability in patients with ALS and kindred disorders, has recently been demonstrated to enhance bulbar function in a Phase II clinical trial.

What this Study Adds {#bcp13745-sec-0007}
====================

The results of this study suggest that even patients who did not substantially improve while on dextromethorphan/quinidine, as determined by patient‐based and clinician‐administered assessments, showed quantifiable improvements in speech that could be detected using objective measures. Objective speech measures may be sensitive objective outcomes in therapeutic drug trials targeting bulbar motor function in ALS.

Introduction {#bcp13745-sec-0008}
============

Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease that causes degeneration of motor neurons. Among the devastating effects of ALS are progressive difficulties with speech, chewing and swallowing. After decades of clinical research, only two drugs have been approved by the US Food and Drug Administration for the treatment of ALS, neither of which have had beneficial effects on speech or swallowing in affected individuals. Edaravone, an antioxidant, was recently observed in a Phase III clinical trial (NCT01492686) to slow the rate of physical decline in a subgroup of patients with ALS [1](#bcp13745-bib-0001){ref-type="ref"}. Riluzole was approved in 1995 for the treatment of ALS after it was demonstrated to increase life expectancy by several months [2](#bcp13745-bib-0002){ref-type="ref"}. Riluzole inhibits the excitatory neurotransmitter glutamate, which may become dysregulated in ALS, leading to overexcitation and subsequent cell damage [3](#bcp13745-bib-0003){ref-type="ref"}. Identification of drugs that mitigate glutamatergic‐induced excitotoxicity continues to be an active area in ALS research [4](#bcp13745-bib-0004){ref-type="ref"}.

Since DM/Q, a combination product containing dextromethorphan (DM) and quinidine, was approved in 2011 for the treatment of emotional lability (pseudobulbar affect) in patients with a variety of neurological disorders, there have been many anecdotal reports of improvement in speech and swallowing in response to treatment [5](#bcp13745-bib-0005){ref-type="ref"}. DM is the active ingredient in many over‐the‐counter cough suppressant medicines and has several known molecular mechanisms of action. The drug exerts molecular promiscuity in that it is a sigma‐1 receptor agonist, a <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=75> antagonist, a <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=76> antagonist, and an inhibitor of the serotonin and norepinephrine transporters [6](#bcp13745-bib-0006){ref-type="ref"}. DM may have neuroprotective effects via such mechanisms [7](#bcp13745-bib-0007){ref-type="ref"}, including attenuation of glutamate‐mediated excitotoxicity [8](#bcp13745-bib-0008){ref-type="ref"}. Quinidine improves the bioavailability of DM by inhibiting cytochrome <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1329>, a liver enzyme that O‐demethylates DM.

Anecdotal reports of improved bulbar function in patients treated with DM/Q prompted a short‐duration (70‐day), multicentre, randomized, double‐blind, crossover Phase II clinical trial to assess the effect of treatment on bulbar motor function in 60 patients with ALS [5](#bcp13745-bib-0005){ref-type="ref"}. The primary efficacy endpoint in that trial was the score on the Center for Neurologic Study Bulbar Function Scale (CNS‐BFS) [5](#bcp13745-bib-0005){ref-type="ref"}, a 21‐item patient‐report scale that assesses speech, swallowing, and salivation. CNS‐BFS scores can range from a low of 21 (no bulbar impairment) to a high of 112 (severe bulbar impairment). The results of that trial demonstrated that DM/Q had a positive effect on bulbar function, with an average improvement of 5.85 points on the CNS‐BFS, a finding that was corroborated by improved bulbar subscores on the ALS Functional Rating

Scale‐Revised (ALSFRS‐R) is a widely used clinician‐administered outcome measure [9](#bcp13745-bib-0009){ref-type="ref"}. To our knowledge, no drug targeting ALS other than DM/Q has been demonstrated to improve speech or swallowing function. Therefore, the effects of DM/Q on bulbar motor function, speech and swallowing is a research priority.

Of particular relevance to this report is the sensitivity of measures used in the Phase II study to assess bulbar function. Although the effect on speech was robust as measured by the speech components of the CNS‐BFS, ALSFRS‐R and a visual analogue scale, statistically detectable improvements were not observed in any of the objective performance‐based measures of bulbar motor function (i.e. timed swallowing, chewing and speech tasks). The absence of improvement in these measures requires further inquiry because: (i) the evidence for a therapeutic effect will be strengthened if the perceived benefits are observed to translate into objective gains in bulbar motor performance; and (ii) although expert consensus regarding best practices for assessment of bulbar function is currently lacking [10](#bcp13745-bib-0010){ref-type="ref"}, recent research has identified computer‐based measures of speech that are more responsive to bulbar motor involvement than the objective speech measures [11](#bcp13745-bib-0011){ref-type="ref"}, [12](#bcp13745-bib-0012){ref-type="ref"}, [13](#bcp13745-bib-0013){ref-type="ref"} used in the DM/Q study [5](#bcp13745-bib-0005){ref-type="ref"}. The latter point is particularly germane to this report because it raises the possibility that relative nonresponders in the original trial, i.e. approximately 30% of all the participants may have experienced speech benefits that were undetected.

The current study aimed to determine if treatment with DM/Q produces measurable changes in speech using high‐precision, computer‐based analyses of the speech signal in a subset of patients in the earlier DM/Q trial. Quantitative speech testing was an exploratory outcome in the original trial. Digital speech recordings were obtained at all visits in only 10 of the 60 participants; therefore, the present analysis could only be undertaken in a limited number of the trial participants. While our findings further validate the positive effects of DM/Q on speech, more importantly, they inform ongoing efforts to identify responsive clinical endpoints for trials that target bulbar motor function [11](#bcp13745-bib-0011){ref-type="ref"}. Drug discovery in ALS has been hampered by a lack of useful biomarkers [14](#bcp13745-bib-0014){ref-type="ref"}, [15](#bcp13745-bib-0015){ref-type="ref"}, so clinical endpoints with high responsiveness to change are needed for identification of candidate drug treatments that could be amplified by increased dosage and exposure or by addition of complementary agents [16](#bcp13745-bib-0016){ref-type="ref"}.

Methods {#bcp13745-sec-0009}
=======

Parent DM/Q trial {#bcp13745-sec-0010}
-----------------

The parent Phase II DM/Q trial (NCT01806857) included data from 60 patients with ALS collected from seven sites. Eligible participants had a diagnosis of ALS according to the World Federation of Neurology El Escorial Criteria [17](#bcp13745-bib-0017){ref-type="ref"} and researcher‐judged bulbar dysfunction, specifically dysarthria and/or dysphagia.

Participants were deemed ineligible for inclusion if they showed evidence of cognitive impairment, had previously used DM/Q or if use of DM/Q was medically contraindicated. A full list of the inclusion/exclusion criteria applied in the DM/Q clinical trial is provided in the report by Smith *et al*. [5](#bcp13745-bib-0005){ref-type="ref"}.

The parent study was a multicentre, randomized, double‐blind, crossover trial. Participants were randomly assigned to receive DM/Q (dextromethorphan hydrobromide 20 mg, quinidine sulphate 10 mg) or placebo for 30 days between visits 1 and 2 and were then crossed over to receive the alternative treatment for 30 days between visits 3 and 4. The study treatments were separated by a washout interval of 10--15 days.

Present study {#bcp13745-sec-0011}
-------------

In this study, speech recordings were obtained from 10 patients in the original cohort of 60 patients with a diagnosis of ALS [5](#bcp13745-bib-0005){ref-type="ref"}. Demographic information and ratings of severity at the initial visit are shown in Table [1](#bcp13745-tbl-0001){ref-type="table"}. The 10 study participants were selected based solely on the availability of speech recordings and were from two of the seven data collection sites involved in the parent study \[Nebraska (*n* = 7) and Cleveland Clinic (*n* = 3)\]. By chance, the subgroup included participants with less severe dysfunction at baseline (mean ALSFRS‐R 38.5 *vs*. 33.8, *P* = 0.05; abnormal speech evaluation 70% *vs*. 96%, *P* = 0.03) who were less likely to experience improvement in the primary endpoint of the parent study (CNS‐BFS total score --1.7 units, *P* = 0.63 *vs*. --6.4 units, *P* \< 0.001). The trial was conducted in accordance with the provisions of the International Conference on Harmonisation Guidelines for Good Clinical Practice [18](#bcp13745-bib-0018){ref-type="ref"} and the Declaration of Helsinki [19](#bcp13745-bib-0019){ref-type="ref"}. All participants at these sites consented to have their speech recorded during each of the four study visits.

###### 

Demographic information of participants

  Patient ID   Sex   Age at enrolment (years)   Onset    Time from symptom onset to enrolment (years, months)
  ------------ ----- -------------------------- -------- ------------------------------------------------------
  **1**        M     42                         Limb     2, 5
  **2**        M     65                         Bulbar   2, 6
  **3**        M     54                         Limb     1, 2
  **4**        M     62                         Bulbar   0, 6
  **5**        M     54                         Limb     12, 0
  **6**        F     64                         Bulbar   1, 4
  **7**        F     75                         Bulbar   1, 5
  **8**        M     38                         Limb     4, 11
  **9**        F     44                         Bulbar   1, 9
  **10**       M     77                         Limb     0, 10

### Outcome measures {#bcp13745-sec-0012}

Eleven outcome variables (Table [2](#bcp13745-tbl-0002){ref-type="table"}) were measured at the beginning (day 1) and end (day 30) of each treatment period (active and placebo) during the trial. At all four data collection sessions, speech recordings were obtained while each participant read a short paragraph (the *Rainbow Passage*) [20](#bcp13745-bib-0020){ref-type="ref"}. Speech samples were recorded using a high‐quality digital audio recording device (Zoom H1 Handy Recorder, Zoom, Hauppauge, NY, USA). The audio recordings were used to obtain clinician‐evaluated speech severity ratings and quantitative measures of speech pausing patterns.

###### 

Study outcome measures

  Outcome                         Type of measurement      Derivation (quantitative measures only)
  ------------------------------- ------------------------ -------------------------------------------------------------------------------
  **ALSFRS‐R Total**              Clinician‐administered   ‐‐
  **ALSFRS‐R Speech**             Clinician‐administered   ‐‐
  **CNS‐BFS Speech**              Patient self‐report      ‐‐
  **SLP severity rating**         Clinician rating         ‐‐
  **Total pause duration (s)**    Quantitative speech      = SUM (duration of individual pause segments \> 300 ms)
  **Number of pause events**      Quantitative speech      = COUNT (individual pause segments \> 300 ms)
  **Pause event duration (s)**    Quantitative speech      = total pause duration (min)/No. of pause events
  **Speech event duration (s)**   Quantitative speech      = total speech duration (min)/No. of speech events
  **Pause time (%)**              Quantitative speech      = total pause time (min)/total response (speech + pause) duration (min) × 100
  **Speaking rate (wpm)**         Quantitative speech      = No. of total words/total response (speech + pause) duration (min)
  **Articulation rate (wpm)**     Quantitative speech      No. of total words/total speech duration (min)

ALSFRS‐R, ALS Functional Rating Scale Revised; CNS‐BFS, Center for Neurologic Study Bulbar Function Scale; SLP, speech‐language pathologist; wpm, words min^--1^

### Clinical speech measures {#bcp13745-sec-0013}

The patient‐reported and clinician‐based measures considered in this study included the CNS‐BFS (speech subscore), ALSFRS‐R (total score and speech subscore), and speech severity ratings by speech‐language pathologists (SLPs). The CNS‐BFS is a patient self‐report scale that assesses three domains of bulbar motor function (i.e. speech, swallowing and salivation) [13](#bcp13745-bib-0013){ref-type="ref"}. Each domain contains seven questions that are rated on scale of 1 (does not apply) to 5 (applies most of the time) for the swallowing and salivation domains, and 1 (does not apply) to 6 (unable to communicate by speaking) for the speech domain. The ALSFRS is a 12‐question survey that is the current gold standard assessment for ALS and is a valid and reliable measure of overall disease severity [9](#bcp13745-bib-0009){ref-type="ref"}, [21](#bcp13745-bib-0021){ref-type="ref"}, [22](#bcp13745-bib-0022){ref-type="ref"}. A speech subscore was extracted based on the patient\'s answer to question 1 of the ALSFRS‐R, which rates overall speech performance on a scale of 4 (normal speech process) to 0 (loss of useful speech).

To obtain speech severity ratings, three SLPs provided dysarthria severity ratings by direct magnitude estimation for each of the four *Rainbow Passage* recordings produced by each patient with ALS [23](#bcp13745-bib-0023){ref-type="ref"}. Direct magnitude estimation involves assigning a value to each speech sample that represents its perceived severity as a ratio relative to a reference sample known as a modulus. The modulus is typically chosen to represent a midpoint on the continuum of the construct being measured and is assigned a value of 100 [23](#bcp13745-bib-0023){ref-type="ref"}, [24](#bcp13745-bib-0024){ref-type="ref"}, [25](#bcp13745-bib-0025){ref-type="ref"}. Using this method, a sample judged to be twice as severe as the modulus would be rated as 200, and a sample judged to be half as severe as the modulus would be rated as 50. For the present study, the modulus chosen was a recording of the *Rainbow Passage* produced by a speaker who was not a subject in the study and was judged by the researchers to have moderate dysarthria.

The SLPs were instructed to listen to the first two sentences of the *Rainbow Passage* recordings from all four visits for each speaker before moving on to the next speaker to ensure that the raters were responding primarily to changes in speech across the sessions and not to the overall severity of speech impairment. The order of presentation of the speech recordings for the four time points was randomized for each speaker, and the SLPs were blinded to the visit number and treatment allocation at each visit. The order of the speakers was also randomized for each SLP. The SLPs were instructed to listen to the modulus once between each set of four speech samples to calibrate their ratings and could listen to each sample as many times as they deemed necessary before assigning a severity rating.

### Quantitative speech measures {#bcp13745-sec-0014}

Prior to the analysis, the speech recordings were reviewed by a laboratory technician and filtered to attenuate ambient noise. An automated Speech Pause Analysis (SPA) programme [26](#bcp13745-bib-0026){ref-type="ref"} was used to algorithmically estimate speech and pause segments in the speech sample based on a minimum pause duration (300 ms) and a minimum speech duration (25 ms).

As shown in Figure [1](#bcp13745-fig-0001){ref-type="fig"}, the SPA programme automatically demarcated pause and speech events and provided counts and duration values for each pause (\>300 ms) and speech (\>25 ms) event, as well as the summed duration of all pause and speech events. These data were used to derive the following five quantitative speech measures from each speech sample: number of pause events, total pause duration (s), percent pause time, (mean) duration of pause event (s), and mean duration of speech events (s). The accuracy of the automatic approach used to measure pauses in continuous speech has been validated against live operator performance [26](#bcp13745-bib-0026){ref-type="ref"}, and the diagnostic accuracy of SPA measures has been also shown to be good for detecting bulbar motor involvement due to ALS [10](#bcp13745-bib-0010){ref-type="ref"}. The SPA output was also used to derive two additional quantitative speech measures, i.e. speaking rate (i.e. number of words per total response duration) and articulation rate (i.e. number of words per total speech duration). Table [2](#bcp13745-tbl-0002){ref-type="table"} describes the derivation of each quantitative speech measure.

![The maximum amplitude of a selected pause region was used to establish a threshold for separating *speech* from *pause* events. Amplitude values above the threshold mark boundaries for speech events and values below the threshold mark boundaries for speech events. Pause and speech event durations below 300 ms and 25 ms, respectively, were not included in the analysis. For each *Rainbow Passage* recording, five primary variables were extracted by Speech Pause Analysis, i.e. (mean) speech event duration, (mean) pause event duration, total pause duration, and percent pause time. The Speech Pause Analysis output was also used in combination with manual syllable counts to derive two additional variables, i.e. speaking rate and articulation rate](BCP-84-2849-g001){#bcp13745-fig-0001}

### Statistical analysis {#bcp13745-sec-0015}

The Wilcoxon signed rank test was used to detect statistically significant differences in patients\' scores between pretesting and post‐testing during the active treatment phase and the placebo phase for each of the 11 outcome measures. Nonparametric tests were used for group comparisons because of the small sample size and the non‐normal distribution of the change in scores for ordinal variables. Cohen\'s *d* effect sizes were computed to quantify the relative magnitude of change per variable in the active treatment phase versus the placebo phase. Effect sizes were calculated using the R *effsize* package [27](#bcp13745-bib-0027){ref-type="ref"}. This study involved repeated measurements on a single sample, so effect size calculations were based on paired differences. For ordinal variables (ALSFRS‐R Total, ALSFRS‐R Speech, CNS‐BFS Speech), Cliff\'s *d* was computed instead of Cohen\'s *d* as a measure of effect size [28](#bcp13745-bib-0028){ref-type="ref"}. Effect sizes for Cohen\'s *d* = 0.5 or Cliff\'s *d* = 0.33 were considered medium effect sizes and those with Cohen\'s *d* = 0.8 or Cliff\'s *d* = 0.474 or greater were considered large effect sizes [29](#bcp13745-bib-0029){ref-type="ref"}.

Nomenclature of targets and ligands {#bcp13745-sec-0016}
-----------------------------------

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [30](#bcp13745-bib-0030){ref-type="ref"}, and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [31](#bcp13745-bib-0031){ref-type="ref"}, [32](#bcp13745-bib-0038){ref-type="ref"}.

Results {#bcp13745-sec-0017}
=======

Summary statistics for the mean pretreatment and post‐treatment values of each outcome measure in the active and placebo phases of the study are shown in Table [3](#bcp13745-tbl-0003){ref-type="table"}, along with the results of pairwise significance testing for each variable. Table [3](#bcp13745-tbl-0003){ref-type="table"} also shows the effect sizes for the change in scores between pretreatment and post‐treatment during the active and placebo phases for each of the 11 outcome variables.

###### 

Descriptive statistics showing the average values for each variable at the pretreatment and post‐treatment time points for the active and placebo phases of the study. Cohen\'s *d* and Cliff\'s *d* effect sizes indicating the magnitude of the change during each phase of the trial are also reported (note: Cohen\'s *d* is larger than Cliff\'s *d* for the same magnitude of change)

![](BCP-84-2849-g002){#nlm-graphic-3}

*P* \< 0.05 denotes the statistical significance of pre vs. post scores across each of the study arms (active, placebo). ± Cohen\'s *d* effect sizes are reported for continuous variables (SLP severity rating, total pause duration, \# pause events, pause event duration, speech event duration, percent pause time, speaking rate, articulation rate); Cliff\'s *d* effect sizes are reported for ordinal variables (ALSFRS‐R Total, ALRSFRS‐R Speech, CNS‐BFS Speech). Arrows indicate the direction of clinician‐judged improvement on a given measure, shown for statistically significant variables only. ALSFRS‐R, ALS Functional Rating Scale Revised; CI, confidence interval; CNS‐BFS, Center for Neurologic Study Bulbar Function Scale; SD, standard deviation; SLP, speech‐language pathologist; wpm, words min^--1^

Clinical speech measures {#bcp13745-sec-0018}
------------------------

As shown in Table [3](#bcp13745-tbl-0003){ref-type="table"}, the effect sizes for pre‐test to post‐test changes in both the active and placebo phases were small for all clinical speech measures including the clinician ratings of speech severity. None of the changes were statistically significant.

Quantitative speech measures {#bcp13745-sec-0019}
----------------------------

On average, participants showed a decrease in percent pause time during the active treatment phase and a minimal change during the placebo treatment phase. This change appeared to be driven by a decrease in total pause duration and an increase in the average duration of speech segments. Statistical comparisons of pretreatment and post‐test measurements for these variables showed medium--large effect sizes for changes in percent pause time (\|*d\|* = 1.08), total pause duration (\|*d*\| = 0.7), and speech event duration (\|*d\|*= 0.7) during the active treatment phase. The effect sizes for these three variables were small for changes between pretest and post‐test during the placebo phase (\|*d\|*= 0.09, 0.32 and 0.07, respectively). The Wilcoxon signed rank tests revealed statistically significant decreases in percent pause time (*Z =* --2.29*, P* = 0.02) and total pause duration (*Z*= --2.09, *P* = 0.04) as well as a significant increase in speech event duration (*Z* = --1.99, *P* = 0.047) during the active treatment phase. There was no significant change in any of these variables between pretesting and post‐testing during the placebo phase. The effect sizes for changes in the remaining four quantitative speech measures (i.e. number of pause events, pause event duration, speaking rate and articulation rate) between pretesting and post‐testing were small in both the active and placebo phases.

Discussion {#bcp13745-sec-0119}
==========

Speech outcomes were analysed in a subset of 10 patients with ALS who were participants in a recent randomized controlled Phase II trial investigating the effects of DM/Q on bulbar motor function [1](#bcp13745-bib-0001){ref-type="ref"}. Multiple speech endpoints were evaluated including objective measures of speech, and patient‐reported and clinician‐based measures. Statistically significant effects were detected for quantitative speech measures using an automated, computer‐based analysis of speech pause patterns [26](#bcp13745-bib-0026){ref-type="ref"}. The observed changes in speech following treatment provide additional evidence for (i) the therapeutic effects of DM/Q on bulbar motor function in persons with ALS and (ii) the high responsiveness of quantitative speech analysis for detecting pharmacological effects on bulbar motor function.

The effects of DM/Q on speech included a decrease in the frequency of pauses and an associated increase in duration of uninterrupted speech. The suggestion that these changes are beneficial is supported by natural history studies demonstrating that bulbar motor deterioration is marked by an increase in both the number and duration of pauses in speech [26](#bcp13745-bib-0026){ref-type="ref"}, [33](#bcp13745-bib-0032){ref-type="ref"}, [34](#bcp13745-bib-0033){ref-type="ref"}. Identifying the mechanisms of these speech improvements will be important for determining if the effects of DM/Q are widely distributed throughout the central nervous system or localized to bulbar motor pathways. Changes in pausing could arise from gains in frontotemporal control over affect and cognitive and linguistic processes [35](#bcp13745-bib-0034){ref-type="ref"}, [37](#bcp13745-bib-0036){ref-type="ref"}, [38](#bcp13745-bib-0037){ref-type="ref"} or reflect a more localized effect on the motor pathways that control speech breathing, voice and articulation [11](#bcp13745-bib-0011){ref-type="ref"}, [26](#bcp13745-bib-0026){ref-type="ref"}, [35](#bcp13745-bib-0034){ref-type="ref"}. A recent study comparing speech pausing behaviour among different subtypes of ALS (e.g. those with primarily bulbar or respiratory involvement) suggest that speech pausing patterns were most aberrant in the subgroup with respiratory involvement [35](#bcp13745-bib-0034){ref-type="ref"}. A more comprehensive speech battery that includes instrumental measures of bulbar motor performance [36](#bcp13745-bib-0035){ref-type="ref"} combined with neural imaging data is required to disentangle the relative contributions of cognitive, linguistic and motor processes to changes in speech pausing patterns in persons with ALS.

The absence of a DM/Q effect on patient‐reported and clinician‐based measures of speech in this subset of participants from the parent trial raises questions about the efficacy of these outcomes measures in ALS intervention trials with only modest sample sizes. Our prior work has also demonstrated the poor diagnostic accuracy of clinician‐based detection of early bulbar involvement with a false‐positive rate as high as 39% [10](#bcp13745-bib-0010){ref-type="ref"}. Our expectation for detecting significant clinical effects on speech in the current study, however, was low because the subgroup of participants studied had, by chance, less severe bulbar dysfunction at baseline than many of the participants in the parent trial and as a group were less responsive to DM/Q treatment [5](#bcp13745-bib-0005){ref-type="ref"}. These mixed findings between clinical and quantitative endpoints underscore the ongoing challenges with choosing endpoints for clinical trials that target bulbar motor functions such as speech and swallowing.

The need for improved surrogate markers of ALS to expedite drug discovery has been long recognized [14](#bcp13745-bib-0014){ref-type="ref"}. Although clinically significant changes were not observed in speech, the finding that changes in speech could be detected using computer‐based analyses provide further support for the high responsiveness of these measurement tools for detecting subclinical changes in bulbar motor function [12](#bcp13745-bib-0012){ref-type="ref"}. Therefore, the identification of these arguably subclinical changes in motor function are critical for improved drug discovery for the following reasons: (i) it suggests that even patients who were considered nonresponders in the parent trial received some physiological benefit from DM/Q; (ii) it justifies additional research to determine if the benefits can be amplified at increased dosages and exposure durations or when the drug is combined with other therapeutic agents; (iii) it helps validate the stratification of responders and nonresponders to the treatment; and (iv) it provides additional information about the biological selectivity of the drug across neural systems.

Overall, the findings of the present study and those of the parent clinical trial confirm the need for continued investigation of the potentially beneficial effects of DM/Q on bulbar motor function, speech and swallowing. Future studies should include larger cohorts and, if safety permits, higher doses and longer exposures. Additional research is also warranted to identify the mechanisms of improved speech and the characteristics of patients who respond to treatment.

The current findings also underscore the need to include quantitative speech motor testing in exploratory studies of drugs and biological interventions for ALS.
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